Global Information
회사소개 | 문의 | 위시리스트

더말 필러 : 의료기기 파이프라인 평가

Dermal Filler - Medical Devices Pipeline Assessment, 2019

리서치사 GlobalData
발행일 2019년 02월 상품 코드 239483
페이지 정보 영문 101 Pages
가격
US $ 4,000 ₩ 4,616,000 PDF by E-mail (Single user license) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 8,000 ₩ 9,232,000 PDF by E-mail (Site license) help
동일 사업장 내 모든 분들이 공유하여 사용할 수 있습니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 2부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 12,000 ₩ 13,848,000 PDF by E-mail (Global license) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없으며, 해외 사업장 및 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 10부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


더말 필러 : 의료기기 파이프라인 평가 Dermal Filler - Medical Devices Pipeline Assessment, 2019
발행일 : 2019년 02월 페이지 정보 : 영문 101 Pages

이 페이지에 게재되어 있는 내용은 최신판과 약간 차이가 있을 수 있으므로 영문목차를 함께 참조하여 주시기 바랍니다. 기타 자세한 사항은 문의 바랍니다.

세계 더말 필러(Dermal Filler) 시장의 주요 파이프라인 제품(의료기기)과 임상시험의 진행 상황에 대해 조사했으며, 제품 특성 비교 분석(임상시험 진행 단계별), 주요 기업의 개요 및 대표적 제품, 최근 시장 동향(자본거래·사업 제휴 등) 등의 정보를 정리하여 전해드립니다.

제1장 목차

제2장 서론

  • 더말 필러 개요

제3장 현재 임상시험중인 제품

  • 파이프라인 제품 : 임상시험 단계별
  • 파이프라인 제품 : 영역별
  • 파이프라인 제품 : 규제 경로별
  • 파이프라인 제품 : 추정 인증 시기별
  • 현재 진행중인 임상시험

제4장 더말 필러 : 각 기업에서 현재 임상시험중인 파이프라인 제품

  • 더말 필러 기업 : 임상시험 단계별 파이프라인 제품
  • 더말 필러 : 임상시험 단계별 파이프라인 제품

제5장 더말 필러 기업·제품 개요

  • Aeon Astron Corporation
    • 파이프라인 제품 및 진행중인 임상시험의 개요
  • Allergan Inc
  • Anika Therapeutics Inc
  • BioPolymer GmbH & Co. KG
  • Cytophil, Inc.
  • Cytosial Biomedic, S.a.s.
  • Dermele Skin Care, LLC
  • EternoGen, LLC
  • FibroGen Inc
  • Galderma SA
  • Innovia LLC
  • Juvenis Ltd.
  • Khorionyx
  • L&C Bio
  • Mentor Worldwide LLC
  • Moma Therapeutics, Inc.
  • Mosaic Medical Technologies, Inc
  • Oligo Medic, Inc.
  • ORGEV Laboratories
  • PetVivo Holdings Inc
  • Sekisui Medical Co Ltd Company
  • Shanghai Haohai Biological Technology Co Ltd
  • Shin Poong PharmCo Ltd
  • Sinclair Pharma PLC
  • Sofregen Medical Inc
  • TEI Biosciences Inc

제6장 더말 필러 시장 : 최근 동향(총 33건)

제7장 제안

도표

KSA 16.12.19

List of Tables

  • Table 1: Dermal Filler - Pipeline Products by Stage of Development
  • Table 2: Dermal Filler - Pipeline Products by Territory
  • Table 3: Dermal Filler - Pipeline Products by Regulatory Path
  • Table 4: Dermal Filler - Pipeline Products by Estimated Approval Date
  • Table 5: Dermal Filler - Ongoing Clinical Trials
  • Table 6: Dermal Filler Companies - Pipeline Products by Stage of Development
  • Table 7: Dermal Filler - Pipeline Products by Stage of Development
  • Table 8: Aeon Astron Corporation Pipeline Products & Ongoing Clinical Trials Overview
  • Table 9: BioDermal Filler - Product Status
  • Table 10: BioDermal Filler - Product Description
  • Table 11: Allergan Plc Pipeline Products & Ongoing Clinical Trials Overview
  • Table 12: HA Threads - Product Status
  • Table 13: HA Threads - Product Description
  • Table 14: JUVEDERM Volbella - Tear Trough - Product Status
  • Table 15: JUVEDERM Volbella - Tear Trough - Product Description
  • Table 16: Juvederm Vollure XC - Product Status
  • Table 17: Juvederm Vollure XC - Product Description
  • Table 18: JUVEDERM VOLUMA - Nose - Product Status
  • Table 19: JUVEDERM VOLUMA - Nose - Product Description
  • Table 20: JUVEDERM Voluma Global - Malar Augmentation - Product Status
  • Table 21: JUVEDERM Voluma Global - Malar Augmentation - Product Description
  • Table 22: VYC-25L Hyaluronic Acid Injectable Gel - Product Status
  • Table 23: VYC-25L Hyaluronic Acid Injectable Gel - Product Description
  • Table 24: Almirall Ltd Pipeline Products & Ongoing Clinical Trials Overview
  • Table 25: Hyaluronic Acid Facial Filler - Product Status
  • Table 26: Hyaluronic Acid Facial Filler - Product Description
  • Table 27: Bioxis Pharmaceuticals Pipeline Products & Ongoing Clinical Trials Overview
  • Table 28: CYTOSIAL Deep Wrinkle - Product Status
  • Table 29: CYTOSIAL Deep Wrinkle - Product Description
  • Table 30: CYTOSIAL Medium - Product Status
  • Table 31: CYTOSIAL Medium - Product Description
  • Table 32: Cytosial Volume - Product Status
  • Table 33: Cytosial Volume - Product Description
  • Table 34: Cytosmile - Product Status
  • Table 35: Cytosmile - Product Description
  • Table 36: MTI-12 - Surgical Repair - Product Status
  • Table 37: MTI-12 - Surgical Repair - Product Description
  • Table 38: BMG Pharma srl Pipeline Products & Ongoing Clinical Trials Overview
  • Table 39: SGA300 - Product Status
  • Table 40: SGA300 - Product Description
  • Table 41: SGA302 - Product Status
  • Table 42: SGA302 - Product Description
  • Table 43: Bmi Korea Co Ltd Pipeline Products & Ongoing Clinical Trials Overview
  • Table 44: BMI4002 - Product Status
  • Table 45: BMI4002 - Product Description
  • Table 46: Celltrix AB Pipeline Products & Ongoing Clinical Trials Overview
  • Table 47: Credurance - Product Status
  • Table 48: Credurance - Product Description
  • Table 49: CollPlant Holdings Ltd Pipeline Products & Ongoing Clinical Trials Overview
  • Table 50: Next Generation Dermal Filler - Product Status
  • Table 51: Next Generation Dermal Filler - Product Description
  • Table 52: EternoGen Aesthetics LLC Pipeline Products & Ongoing Clinical Trials Overview
  • Table 53: Cellifique - Product Status
  • Table 54: Cellifique - Product Description
  • Table 55: Genzyme Corp Pipeline Products & Ongoing Clinical Trials Overview
  • Table 56: PREVELLE Lift - Product Status
  • Table 57: PREVELLE Lift - Product Description
  • Table 58: Innovia LLC Pipeline Products & Ongoing Clinical Trials Overview
  • Table 59: Wrinkle Filler - Product Status
  • Table 60: Wrinkle Filler - Product Description
  • Table 61: Juvenis Ltd Pipeline Products & Ongoing Clinical Trials Overview
  • Table 62: Tenergel - Product Status
  • Table 63: Tenergel - Product Description
  • Table 64: Khorionyx SA Pipeline Products & Ongoing Clinical Trials Overview
  • Table 65: Autologous Globin Dermal Filler - Product Status
  • Table 66: Autologous Globin Dermal Filler - Product Description
  • Table 67: Medy-Tox Inc Pipeline Products & Ongoing Clinical Trials Overview
  • Table 68: MT943 - Product Status
  • Table 69: MT943 - Product Description
  • Table 70: Neuramis Deep Lidocaine - Product Status
  • Table 71: Neuramis Deep Lidocaine - Product Description
  • Table 72: Neuramis Volume Lidocaine - Product Status
  • Table 73: Neuramis Volume Lidocaine - Product Description
  • Table 74: Medy-Tox Inc - Ongoing Clinical Trials Overview
  • Table 75: Neuramis Volume Lidocaine - Clinical Study of Neuramis Volume Lidocaine to Evaluate the Efficacy and Safety for Temporary Restoring the Mid-face Volume
  • Table 76: Mesoestetic Pharma Group SL Pipeline Products & Ongoing Clinical Trials Overview
  • Table 77: mRDX-02-17 - Product Status
  • Table 78: mRDX-02-17 - Product Description
  • Table 79: Mesoestetic Pharma Group SL - Ongoing Clinical Trials Overview
  • Table 80: mRDX-02-17 - A Multicentre, Open-label, Interventional, Pilot Trial to Assess the Performance and Tolerance of mRDX-02-17 Dermal Filler in the Facial Rejuvenation

List of Figures

  • Figure 1: Dermal Filler - Pipeline Products by Stage of Development
  • Figure 2: Dermal Filler - Pipeline Products by Territory
  • Figure 3: Dermal Filler - Pipeline Products by Regulatory Path
  • Figure 4: Dermal Filler - Pipeline Products by Estimated Approval Date
  • Figure 5: Dermal Filler - Ongoing Clinical Trials

GlobalData's Medical Devices sector report, "Dermal Filler - Medical Devices Pipeline Assessment, 2019" provides an overview of Dermal Filler currently in pipeline stage.

The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Dermal Filler pipeline products.

This report is prepared using data sourced from in-house databases, secondary and primary research by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope

  • Extensive coverage of the Dermal Filler under development
  • The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
  • The report reviews the major players involved in the development of Dermal Filler and list all their pipeline projects
  • The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
  • The report provides key clinical trial data of ongoing trials specific to pipeline products
  • Recent developments in the segment / industry.

Reasons to buy

The report enables you to -

  • Formulate significant competitor information, analysis, and insights to improve R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of Dermal Filler under development
  • Develop market-entry and market expansion strategies
  • Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
  • In-depth analysis of the product's current stage of development, territory and estimated launch date.

Table of Contents

1 Table of Contents

  • 1.1 List of Tables
  • 1.2 List of Figures

2 Introduction

  • 2.1 Dermal Filler Overview

3 Products under Development

  • 3.1 Dermal Filler - Pipeline Products by Stage of Development
  • 3.2 Dermal Filler - Pipeline Products by Territory
  • 3.3 Dermal Filler - Pipeline Products by Regulatory Path
  • 3.4 Dermal Filler - Pipeline Products by Estimated Approval Date
  • 3.5 Dermal Filler - Ongoing Clinical Trials

4 Dermal Filler - Pipeline Products under Development by Companies

  • 4.1 Dermal Filler Companies - Pipeline Products by Stage of Development
  • 4.2 Dermal Filler - Pipeline Products by Stage of Development

5 Dermal Filler Companies and Product Overview

  • 5.1 Aeon Astron Corporation Company Overview
  • 5.2 Allergan Plc Company Overview
  • 5.3 Almirall Ltd Company Overview
  • 5.4 Bioxis Pharmaceuticals Company Overview
  • 5.5 BMG Pharma srl Company Overview
  • 5.6 Bmi Korea Co Ltd Company Overview
  • 5.7 Celltrix AB Company Overview
  • 5.8 CollPlant Holdings Ltd Company Overview
  • 5.9 EternoGen Aesthetics LLC Company Overview
  • 5.10 Genzyme Corp Company Overview
  • 5.11 Innovia LLC Company Overview
  • 5.12 Juvenis Ltd Company Overview
  • 5.13 Khorionyx SA Company Overview
  • 5.14 Medy-Tox Inc Company Overview
  • 5.15 Mesoestetic Pharma Group SL Company Overview
  • 5.16 Moma Therapeutics, Inc. Company Overview
  • 5.17 N8 Medical Inc Company Overview
  • 5.18 Oligo Medic Inc Company Overview
  • 5.19 PB&B SA Company Overview
  • 5.20 PetVivo Holdings Inc Company Overview
  • 5.21 Regenscientific Company Overview
  • 5.22 Samyang Biopharmaceuticals Corp Company Overview
  • 5.23 Sebana Medical Ltd Company Overview
  • 5.24 Sekisui Medical Co Ltd Company Overview
  • 5.25 Shanghai Haohai Biological Technology Co Ltd Company Overview
  • 5.26 Shin Poong PharmCo Ltd Company Overview
  • 5.27 Sinclair Pharma PLC Company Overview
  • 5.28 Sofregen Medical Inc Company Overview
  • 5.29 TEI Biosciences Inc Company Overview
  • 5.30 University of California Santa Barbara Company Overview

6 Dermal Filler- Recent Developments

  • 6.1 Jul 19, 2018: Suneva Medical promotes Patricia Altavilla to chief operating officer
  • 6.2 Jul 05, 2018: Sinclair Pharma: Trading Update for the 6 months to 30 June 2018
  • 6.3 Jun 04, 2018: SWAG Penis Enhancement Procedure Developed by Top Plastic Surgeon Achieving Optimal Results
  • 6.4 May 21, 2018: Nestle Skin Health Announces the FDA Approval of Restylane Lyft for Hands, the First and Only Hyaluronic Acid (HA) Dermal Filler for Use in the Back of Hands
  • 6.5 May 15, 2018: BTG: Final Results For year ended 31 March 2018
  • 6.6 May 09, 2018: FibroGen Reports First Quarter 2018 Financial Results
  • 6.7 May 08, 2018: Smith & Nephew: Change of Directorate
  • 6.8 May 08, 2018: CollPlant Files U.S. Patent Application for Next Generation Dermal Filler
  • 6.9 May 03, 2018: Smith & Nephew First Quarter 2018 Trading Report
  • 6.10 May 02, 2018: Anika Reports First Quarter 2018 Financial Results
  • 6.11 Apr 30, 2018: Sinclair Pharma: Preliminary results for 12 months ended 31 December 2017
  • 6.12 Apr 30, 2018: Sinclair secures €23 million debt facility
  • 6.13 Apr 09, 2018: Merz Aesthetics Launches New Belotero Lips Dermal Filler Products
  • 6.14 Apr 04, 2018: Namal Nawana appointed Chief Executive Officer of Smith & Nephew
  • 6.15 Mar 20, 2018: Governor Abbott Announces Smith & Nephew Adding New Jobs In Fort Worth
  • 6.16 Mar 05, 2018: Anika Therapeutics Names Joseph Darling As CEO And Director
  • 6.17 Mar 01, 2018: Smith & Nephew: Change in Directorate
  • 6.18 Feb 27, 2018: FibroGen Announces Fourth Quarter and Full Year 2017 Financial Results
  • 6.19 Feb 21, 2018: Anika Announces Fourth Quarter and Full Year 2017 Financial Results
  • 6.20 Feb 16, 2018: Merz North America to Highlight Treatments at American Academy of Dermatology Annual Meeting
  • 6.21 Feb 08, 2018: Smith & Nephew Fourth Quarter Trading and Full Year 2017 Results
  • 6.22 Jan 31, 2018: Smith & Nephew Appoints Roland Diggelmann As Non-Executive Director
  • 6.23 Jan 31, 2018: Appointment of Roland Diggelmann as Non-Executive Director
  • 6.24 Jan 16, 2018: Galderma Introduces Restylane Skinboosters
  • 6.25 Jan 16, 2018: Sinclair Pharma: Ellanse Approved for Brazil

7 Appendix

  • 7.1 Methodology
  • 7.2 About GlobalData
  • 7.3 Contact Us
  • 7.4 Disclaimer
Back to Top
전화 문의
F A Q
 
BCC Research